Mice receiving Cav-1^−/− T cells show prolonged survival. (A) Recipients were transplanted with 5 × 10⁶ BM cells and 3 × 10⁵ T cells (Cav-1^+/+ or Cav-1^−/−) each. Survival was monitored for 100 days. The experiment was repeated 4 times (n = 34 per group). (B) On day 7 after allo-HCT, GVHD target organs such as the liver (left), small intestine (middle), and large intestine (right) were isolated. A histopathological scoring was performed by an experienced pathologist who was single-blinded (pooled from 2 experiments, n = 7 or 8 as indicated). (C) On days 7 to 10 after allo-HCT, recipient mice were analyzed for IL-6 serum levels (pooled from 2 experiments, n = 3 or 6 as indicated, and each data point represents a mouse). (D) BALB/c WT recipients treated as in (A) were subsequently transplanted with 5 × 10⁶ BM cells and 3 × 10⁵ T cells from either Y14F/Y14F transgenic, C57BL/6 WT, or Cav-1^−/− mice. Survival was monitored for 100 days. (Y14F/Y14F vs WT, P = .7643; Y14F/Y14F vs Cav-1^−/−, P = .0234; pooled from 2 experiments, n = 10). Tc, T cells.